Home Proteases Thrombin inhibitor Heparin Sodium

research use only

Heparin Sodium Anticoagulant

Cat.No.S1346

Heparin sodium, a sulfated polysaccharide belonging to the family of glycosaminoglycans, has numerous important biological activities associated with its interaction with diverse proteins. Heparin is used as an anticoagulant primarily through its interaction with AT III by enhancing AT-IIImediated inhibition of blood coagulation factors, including thrombin and factor Xa. Heparin prevents the induction of autophagy.
Heparin Sodium Thrombin inhibitor Chemical Structure

Chemical Structure

Jump to

Quality Control

Batch: Purity: 98.14%
98.14

Solubility

In vitro
Batch:

Water : 162 mg/mL

DMSO : Insoluble
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight Formula

(C12H16NS2Na3)20

 Storage (From the date of receipt)
CAS No. 9041-08-1 -- Storage of Stock Solutions

Synonyms N/A SMILES CCC1CC(N[R])C(OC1CO[S]([O-])(=O)=O)OC2C(O)C(O)C(OC3C(CO[R])OC(OC4C(O)C(O[S]([O-])(=O)=O)C(OC5C(O)C(N[S]([O-])(=O)=O)C(C)OC5CO[S]([O-])(=O)=O)OC4C([O-])=O)C(N[S]([O-])(=O)=O)C3[S]([O-])(=O)=O)OC2C([O-]

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC50/Ki
Antithrombin III
In vitro

Heparin is widely used as an anticoagulant drug based on its ability to accelerate the rate at which antithrombin inhibits serine proteases in the blood coagulation cascade. Heparin and the structurally related heparan sulfate are complex linear polymers comprised of a mixture of chains of different length, having variable sequences. Heparin interactes most tightly with peptides containing a complementary binding site of high positive charge density. Heparin and heparan sulfate predominantly exhibit linear helical secondary structures with sulfo and carboxyl groups displayed at defined intervals and in defined orientations along the polysaccharide backbone. Heparin resembles DNA as both are highly charged linear polymers that behave as polyelectrolytes. Heparin is believed to function as an anticoagulant primarily through its interaction with AT III by enhancing AT-III-mediated inhibition of blood coagulation factors, including thrombin and factor Xa. Heparin binds to AT III and thrombin in a ternary complex, increasing the bimolecular rate constant for the inhibition of thrombin by a factor of 2000. Heparin is principally located in the granules of tissue mast cells that are closely associated with the immune response. Heparin makes numerous contacts with both FGF-2 and FGFR-1 stabilizing FGF–FGFR binding. Heparin also makes contacts with the FGFR-1 of the adjacent FGF–FGFR complex, thus seeming to promote FGFR dimerization.

References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-07-27)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06494878 RECRUITING
Venous Thromboembolism; Postpartum Period; Aspirin; Low Molecular Weight Heparin
University of Calgary
 2026-06-04 PHASE3
NCT07140211 RECRUITING
Venous Thromboembolism (VTE); Postpartum
Marc Blondon
 2025-10-15 PHASE3
NCT07783880 NOT_YET_RECRUITING
Myocardial Infarction; Percutaneous Coronary Intervention (PCI); Medical Treatment; Coronary Computed Tomographic Angiography; Computed Tomography; Optical Coherence Tomography (OCT)
3W-Research Collaboration Group
 2026-10-01
NCT06753786 RECRUITING
Venous Thromboembolism; Pulmonary Embolism; Intracerebral Hemorrhage; Deep Vein Thrombosis
Pirogov Russian National Research Medical University
 2024-10-21
NCT06381661 RECRUITING
Sepsis
Assistance Publique - Hôpitaux de Paris
 2026-07-09 PHASE2
NCT06714864 RECRUITING
Catheter-Related Infections
CorMedix Therapeutics
 2025-07-08 PHASE4

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.